scholarly journals Saccharin Sulfonamides as Inhibitors of Carbonic Anhydrases I, II, VII, XII, and XIII

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Vaida Morkūnaitė ◽  
Lina Baranauskienė ◽  
Asta Zubrienė ◽  
Visvaldas Kairys ◽  
Jekaterina Ivanova ◽  
...  

A series of modified saccharin sulfonamides have been designed as carbonic anhydrase (CA) inhibitors and synthesized. Their binding to CA isoforms I, II, VII, XII, and XIII was measured by the fluorescent thermal shift assay (FTSA) and isothermal titration calorimetry (ITC). Saccharin bound the CAs weakly, exhibiting the affinities of 1–10 mM for four CAs except CA I where binding could not be detected. Several sulfonamide-bearing saccharines exhibited strong affinities of 1–10 nM towards particular CA isoforms. The functional group binding Gibbs free energy additivity maps are presented which may provide insights into the design of compounds with increased affinity towards selected CAs.

Author(s):  
Vaida Paketurytė ◽  
Asta Zubrienė ◽  
Wen-Yih Chen ◽  
Sandro Keller ◽  
Margarida Bastos ◽  
...  

2009 ◽  
Vol 10 (6) ◽  
pp. 2662-2680 ◽  
Author(s):  
Asta Zubrienė ◽  
Jurgita Matulienė ◽  
Lina Baranauskienė ◽  
Jelena Jachno ◽  
Jolanta Torresan ◽  
...  

2021 ◽  
pp. 247255522110194
Author(s):  
Stefan Gradl ◽  
Holger Steuber ◽  
Joerg Weiske ◽  
Magda M. Szewczyk ◽  
Norbert Schmees ◽  
...  

SMYD3 (SET and MYND domain-containing protein 3) is a protein lysine methyltransferase that was initially described as an H3K4 methyltransferase involved in transcriptional regulation. SMYD3 has been reported to methylate and regulate several nonhistone proteins relevant to cancer, including mitogen-activated protein kinase kinase kinase 2 (MAP3K2), vascular endothelial growth factor receptor 1 (VEGFR1), and the human epidermal growth factor receptor 2 (HER2). In addition, overexpression of SMYD3 has been linked to poor prognosis in certain cancers, suggesting SMYD3 as a potential oncogene and attractive cancer drug target. Here we report the discovery of a novel SMYD3 inhibitor. We performed a thermal shift assay (TSA)-based high-throughput screening (HTS) with 410,000 compounds and identified a novel benzodiazepine-based SMYD3 inhibitor series. Crystal structures revealed that this series binds to the substrate binding site and occupies the hydrophobic lysine binding pocket via an unprecedented hydrogen bonding pattern. Biochemical assays showed substrate competitive behavior. Following optimization and extensive biophysical validation with surface plasmon resonance (SPR) analysis and isothermal titration calorimetry (ITC), we identified BAY-6035, which shows nanomolar potency and selectivity against kinases and other PKMTs. Furthermore, BAY-6035 specifically inhibits methylation of MAP3K2 by SMYD3 in a cellular mechanistic assay with an IC50 <100 nM. Moreover, we describe a congeneric negative control to BAY-6035. In summary, BAY-6035 is a novel selective and potent SMYD3 inhibitor probe that will foster the exploration of the biological role of SMYD3 in diseased and nondiseased tissues.


Sign in / Sign up

Export Citation Format

Share Document